Raquel Gallagher

Raquel Gallagher is a Biomedical Research Associate at Reboot Rx, where she supports clinical and policy initiatives to advance the use of repurposed generic drugs in cancer care. She focuses on translating scientific and regulatory evidence into practical strategies.

Raquel has contributed to several foundational initiatives, including co-authoring multiple policy publications examining regulatory pathways for nonprofit-led drug repurposing. She also supports the development of Reboot Rx’s evidence resources, helping make complex clinical evidence clear and accessible for clinicians.

Prior to Reboot Rx, Raquel conducted research at Massachusetts General Hospital, studying COVID-19 vaccine responses in patients with multiple myeloma. She holds a Bachelor of Arts in Biological Sciences, with a concentration in Human Health and Disease, from Northwestern University.